Dyselectrolytemias after single dose of pamidronate administration.
Bisphosphonate such as pamidronate initially described for the treatment of neoplastic hypercalcemia, currently is being used off label to treat sever hypercalcemia of any etiology. Multiple dyselectrolytemias are a potential adverse effect of this drug, and are considered infrequent. We describe a case of transient electrolyte abnormalities after single dose of 60 mg intravenous pamidronate.